AR084545A1 - Preparacion de absorcion percutanea que contiene rivastigmina - Google Patents
Preparacion de absorcion percutanea que contiene rivastigminaInfo
- Publication number
- AR084545A1 AR084545A1 ARP110104888A ARP110104888A AR084545A1 AR 084545 A1 AR084545 A1 AR 084545A1 AR P110104888 A ARP110104888 A AR P110104888A AR P110104888 A ARP110104888 A AR P110104888A AR 084545 A1 AR084545 A1 AR 084545A1
- Authority
- AR
- Argentina
- Prior art keywords
- resin
- percutaneous absorption
- absorption preparation
- rivastigmine
- glycol
- Prior art date
Links
- 238000010521 absorption reaction Methods 0.000 title abstract 5
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 title abstract 4
- 229960004136 rivastigmine Drugs 0.000 title abstract 4
- 229920005989 resin Polymers 0.000 abstract 5
- 239000011347 resin Substances 0.000 abstract 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 abstract 3
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 abstract 3
- 239000004014 plasticizer Substances 0.000 abstract 3
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 abstract 3
- 206010012289 Dementia Diseases 0.000 abstract 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 abstract 2
- 239000013032 Hydrocarbon resin Substances 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 2
- 150000002148 esters Chemical class 0.000 abstract 2
- 229920006270 hydrocarbon resin Polymers 0.000 abstract 2
- 239000007788 liquid Substances 0.000 abstract 2
- 229920000346 polystyrene-polyisoprene block-polystyrene Polymers 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 abstract 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 abstract 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 abstract 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 abstract 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 229920006271 aliphatic hydrocarbon resin Polymers 0.000 abstract 1
- DNTGGZPQPQTDQF-XBXARRHUSA-N crotamiton Chemical compound C/C=C/C(=O)N(CC)C1=CC=CC=C1C DNTGGZPQPQTDQF-XBXARRHUSA-N 0.000 abstract 1
- 229960003338 crotamiton Drugs 0.000 abstract 1
- 235000014113 dietary fatty acids Nutrition 0.000 abstract 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000000194 fatty acid Substances 0.000 abstract 1
- 229930195729 fatty acid Natural products 0.000 abstract 1
- 150000004665 fatty acids Chemical class 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 239000001087 glyceryl triacetate Substances 0.000 abstract 1
- 235000013773 glyceryl triacetate Nutrition 0.000 abstract 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 abstract 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 abstract 1
- 239000003921 oil Substances 0.000 abstract 1
- 235000019198 oils Nutrition 0.000 abstract 1
- 239000003208 petroleum Substances 0.000 abstract 1
- 229920001225 polyester resin Polymers 0.000 abstract 1
- 239000004645 polyester resin Substances 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 abstract 1
- 229960001860 salicylate Drugs 0.000 abstract 1
- 229940032094 squalane Drugs 0.000 abstract 1
- 229940031439 squalene Drugs 0.000 abstract 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 abstract 1
- 150000003505 terpenes Chemical class 0.000 abstract 1
- 235000007586 terpenes Nutrition 0.000 abstract 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 abstract 1
- 229960002622 triacetin Drugs 0.000 abstract 1
- 239000001069 triethyl citrate Substances 0.000 abstract 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 abstract 1
- 235000013769 triethyl citrate Nutrition 0.000 abstract 1
- 235000015112 vegetable and seed oil Nutrition 0.000 abstract 1
- 239000008158 vegetable oil Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00544—Plasters form or structure
- A61F2013/00646—Medication patches, e.g. transcutaneous
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Botany (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Preparación de absorción percutánea para el tratamiento de la demencia que comprende rivastigmina o su sal farmacéuticamente aceptable como un ingrediente activo, un copolímero en bloque de estireno-isopreno-estireno, una resina fijadora, y un plastificante, cuya preparación contiene una pequeña cantidad de rivastigmina pero permite una cantidad suficiente de ingrediente activo penetrado en la piel para lograr un tratamiento efectivo de demencia.Reivindicación 1: Una preparación de absorción percutánea que comprende: (a) una capa soporte; y (b) una capa que contiene droga que comprende rivastigmina de base libre o una sal farmacéuticamente aceptable de la misma, un copolímero en bloque de estireno-isopreno-estireno, una resina fijadora, y un plastificante. Reivindicación 6: La preparación de absorción percutánea de la reivindicación 5, en donde la resina fijadora es al menos una seleccionada del grupo que consiste en una resina de hidrocarburo, una resina de hidrocarburo alifática, una resina de hidrocarburo hidrogenada, una resina a base de rosina, una resina a base de terpeno, y una resina de poliéster. Reivindicación 7: La preparación de absorción percutánea de la reivindicación 1 ó 2, en donde el plastificante es al menos uno seleccionado del grupo que consiste de petróleo, escualano, escualeno, aceite vegetal, aceite sintético, éster de ácido dibásico, goma líquida, éster de ácido graso líquido, glicol dietileno, glicol de polietileno, glicol de salicilato, glicol de propileno, glicol de dipropileno, triacetina, citrato de trietil, y crotamitón.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020100134692A KR101788802B1 (ko) | 2010-12-24 | 2010-12-24 | 리바스티그민을 함유하는 경피흡수제제 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR084545A1 true AR084545A1 (es) | 2013-05-22 |
Family
ID=46314648
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP110104888A AR084545A1 (es) | 2010-12-24 | 2011-12-22 | Preparacion de absorcion percutanea que contiene rivastigmina |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20130267916A1 (es) |
| EP (1) | EP2654739B1 (es) |
| JP (1) | JP5951637B2 (es) |
| KR (1) | KR101788802B1 (es) |
| CN (1) | CN103313705B (es) |
| AR (1) | AR084545A1 (es) |
| AU (1) | AU2011345574B2 (es) |
| BR (1) | BR112013016266A2 (es) |
| NZ (1) | NZ611920A (es) |
| WO (1) | WO2012087047A2 (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20150051559A1 (en) * | 2012-04-05 | 2015-02-19 | Sparsha Pharma International Private Limited | Transdermal patch for treatment of dementia or alzheimer type dementia |
| US10758494B2 (en) | 2012-06-12 | 2020-09-01 | KM Transderm Ltd. | Rivastigmine-containing adhesive patch |
| US9895320B2 (en) * | 2012-09-28 | 2018-02-20 | KM Transderm Ltd. | Transdermal patch with different viscosity hydrocarbon oils in the drug layer and the adhesive layer |
| WO2014111790A2 (en) | 2013-01-15 | 2014-07-24 | Zydus Technologies Limited | Stable transdermal pharmaceutical drug delivery system comprising rivastigmine |
| TWI745577B (zh) * | 2013-06-12 | 2021-11-11 | 日商Ｋｍ特蘭斯達股份有限公司 | 經皮吸收製劑 |
| JP2017039706A (ja) * | 2015-08-19 | 2017-02-23 | ニチバン株式会社 | 皮膚貼付用ハイドロコロイド型粘着剤組成物、及びこれを用いた貼付材 |
| JP7531821B2 (ja) * | 2015-11-16 | 2024-08-13 | ノーヴェン ファーマシューティカルズ インコーポレイテッド | 経皮薬物送達システムのための伸縮可能なバッキング層 |
| JP6864968B2 (ja) * | 2016-08-22 | 2021-04-28 | 救急薬品工業株式会社 | 貼付剤 |
| WO2018155682A1 (ja) * | 2017-02-27 | 2018-08-30 | 帝國製薬株式会社 | リバスチグミン含有経皮吸収型製剤 |
| KR101892270B1 (ko) * | 2017-04-07 | 2018-08-27 | 주식회사 삼양사 | 피부자극을 최소화 할 수 있는 경피 흡수용 패취 시스템 |
| US12290501B2 (en) | 2017-07-19 | 2025-05-06 | Teikoku Seiyaku Co., Ltd. | Rivastigmine-containing transdermal absorption preparation |
| BR112020024923A2 (pt) * | 2018-06-19 | 2021-03-09 | Lts Lohmann Therapie-Systeme Ag | Sistema terapêutico transdérmico contendo rivastigmina |
| CN108926549A (zh) * | 2018-09-27 | 2018-12-04 | 安徽安科余良卿药业有限公司 | 卡巴拉汀凝胶贴膏及其制备方法 |
| CN111195242B (zh) * | 2018-11-16 | 2022-10-25 | 得生制药股份有限公司 | 经皮吸收贴片 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9800526D0 (en) * | 1998-01-12 | 1998-03-11 | Ciba Geigy Ag | Organic compounds |
| FI20000810A0 (fi) * | 2000-04-06 | 2000-04-06 | Orion Yhtymae Oyj | Jauheinhalaattori |
| EP1437130A4 (en) * | 2001-10-17 | 2009-08-26 | Hisamitsu Pharmaceutical Co | PERCUTANEOUS ABSORPTION PREPARATIONS |
| DK1477164T3 (da) * | 2002-02-19 | 2012-07-09 | Hisamitsu Pharmaceutical Co | Perkutant plaster af absorptionstypen |
| TWI389709B (zh) * | 2005-12-01 | 2013-03-21 | Novartis Ag | 經皮治療系統 |
| US9248104B2 (en) | 2006-08-17 | 2016-02-02 | Core Tech Solutions, Inc. | Transdermal methods and systems for treating Alzheimer's disease |
| JP5243254B2 (ja) * | 2006-10-11 | 2013-07-24 | 久光製薬株式会社 | 結晶含有貼付剤 |
| JP2009022730A (ja) * | 2007-06-18 | 2009-02-05 | Kyoritsu Yakuhin Kogyo Kk | 貼付剤 |
| KR101175925B1 (ko) * | 2009-01-02 | 2012-08-22 | 대화제약 주식회사 | 리바스티그민의 간단한 경피흡수제 |
-
2010
- 2010-12-24 KR KR1020100134692A patent/KR101788802B1/ko active Active
-
2011
- 2011-12-22 WO PCT/KR2011/009994 patent/WO2012087047A2/en not_active Ceased
- 2011-12-22 JP JP2013546023A patent/JP5951637B2/ja not_active Expired - Fee Related
- 2011-12-22 BR BR112013016266-0A patent/BR112013016266A2/pt not_active IP Right Cessation
- 2011-12-22 NZ NZ611920A patent/NZ611920A/en not_active IP Right Cessation
- 2011-12-22 US US13/994,788 patent/US20130267916A1/en not_active Abandoned
- 2011-12-22 EP EP11851699.6A patent/EP2654739B1/en active Active
- 2011-12-22 AU AU2011345574A patent/AU2011345574B2/en not_active Ceased
- 2011-12-22 AR ARP110104888A patent/AR084545A1/es unknown
- 2011-12-22 CN CN201180062504.0A patent/CN103313705B/zh not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP2654739A4 (en) | 2016-07-06 |
| JP5951637B2 (ja) | 2016-07-13 |
| CN103313705A (zh) | 2013-09-18 |
| EP2654739A2 (en) | 2013-10-30 |
| WO2012087047A2 (en) | 2012-06-28 |
| EP2654739B1 (en) | 2020-07-22 |
| WO2012087047A3 (en) | 2012-08-16 |
| KR101788802B1 (ko) | 2017-10-20 |
| NZ611920A (en) | 2015-05-29 |
| US20130267916A1 (en) | 2013-10-10 |
| KR20120072796A (ko) | 2012-07-04 |
| AU2011345574A1 (en) | 2013-07-11 |
| JP2014508728A (ja) | 2014-04-10 |
| CN103313705B (zh) | 2015-09-30 |
| AU2011345574B2 (en) | 2015-07-16 |
| BR112013016266A2 (pt) | 2018-06-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR084545A1 (es) | Preparacion de absorcion percutanea que contiene rivastigmina | |
| BR112012030653A2 (pt) | composição tópica em aerosol, estável ao armazenamento e substancialmente anidra, e, recipiente pressurizado | |
| AR096521A1 (es) | Sistema de liberación transdérmico, uso, método de fabricación | |
| EP4338805A3 (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| JO3071B1 (ar) | تركيبة مُعقدة تعطى بالفم مشتملة على إيستر أحماض دهنية أوميغا 3 ومُثبط مختزل هيدروكسي مثيل جلوتاريل ــ ملونات | |
| TWI501790B (zh) | Contains percutaneous absorption preparations from Donepezil | |
| AR089201A1 (es) | Sistema de suministro transdermico | |
| WO2008069283A1 (ja) | 外用医薬組成物及び貼付剤 | |
| AR066214A1 (es) | Derivados de pirazolopirimidinas como inhibidores de quinasas dependientes de ciclinas. usos y composiciones farmaceuticas | |
| EA200701913A1 (ru) | Лечение статином, омега-3 жирными кислотами и их комбинированным продуктом | |
| AR090491A1 (es) | Tratamiento de la esclerosis multiple con una combinacion de laquinimod y fumarato de dimetilo | |
| RU2011139638A (ru) | Сублингвальная фармацевтическая композиция, содержащая нейтральное масло | |
| AR093940A1 (es) | Sistema de liberacion transdermica, metodo de preparacion | |
| RU2012120745A (ru) | Трансдермально абсорбируемый состав, содержащий донепезил | |
| CN107427472B (zh) | 贴附剂 | |
| KR20110124771A (ko) | 진통·항염증제 함유 외용제 | |
| JPWO2009031318A1 (ja) | 鎮痛・抗炎症剤含有外用剤 | |
| AR067446A1 (es) | Un medicamento para tratar higado graso que comprende cilostazol | |
| AR084235A1 (es) | Composiciones farmaceuticas que comprenden alisporivir | |
| AR095538A1 (es) | Composiciones farmacéuticas de ésteres de testosterona de cadena larga lipoequilibrados para la administración oral | |
| ECSP13013095A (es) | Composición farmacéutica que comprende fexofenadina | |
| AR086447A1 (es) | Composicion farmaceutica que comprende ketoprofeno | |
| EA201692083A1 (ru) | Фармацевтическая композиция для ветеринарии и ее применение | |
| JPWO2013183407A1 (ja) | ミルタザピン含有経皮吸収型貼付製剤 | |
| KR20160113120A (ko) | 에메다스틴 함유 테이프제 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |